title: Improvement of clinical staging in cervical cancer with serum squamous cell carcinoma antigen and CA 125 determinations.
abstract: Staging of cervical cancer is routinely performed by means of examination under anesthesia in combination with radiographic and/or endoscopic techniques. This "clinical" staging leads to 10-25% misclassification, mostly due to positive lymph nodes or lymph or blood vessel invasion. Determination of pretreatment squamous cell carcinoma antigen (SCC) and CA 125 serum levels may solve part of this staging problem and may improve the selection of the most appropriate individual therapy. Using 2.5 ng/ml (SCC) and 35 U/ml (CA 125) as cutoff levels, we studied 99 patients retrospectively. Elevated levels were found in 27% (SCC) and 23% (CA 125). In clinical stage IB or IIA disease 45/81 patients had positive nodes or lymph or blood vessel invasion at operation. Of these patients 49% had elevated serum levels of SCC or CA 125. Strongest correlation was found with blood vessel invasion (57%). Only 19% of low-stage patients without evidence of vascular spread of disease had positive levels. The positive predictive value of SCC and CA 125 for detection of vascular spread of disease in low-stage cervical cancer was 76%. In most centers surgery is the primary treatment of choice in low-stage cervical cancer. Nevertheless, with respect to patient survival, results of primary surgery and primary radiotherapy are comparable. Radiotherapy given in an adjuvant setting leads to a high incidence of severe complications. In order to overcome part of these complications one should consider radiotherapy as the primary therapy of choice in patients with clinical stage IB or IIA cervical cancer with elevated pretreatment SCC or CA 125 levels.
authors.affiliation: Department of Obstetrics and Gynecology, University Hospital, Nijmegen, The Netherlands.
authors.forename: L F
authors.initials: LF
authors.lastname: Massuger
authors.forename: N P
authors.initials: NP
authors.lastname: Koper
authors.forename: C M
authors.initials: CM
authors.lastname: Thomas
authors.forename: K E
authors.initials: KE
authors.lastname: Dom
authors.forename: C P
authors.initials: CP
authors.lastname: Schijf
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D015843:Serpins; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000473:pathology*
chemical_list: D000951:Antigens, Neoplasm; D018394:CA-125 Antigen; D015843:Serpins; C051072:squamous cell carcinoma-related antigen